IPAX-2 study completes enrolment and confirms dosing for glioblastoma
May 19, 2026 | 10:35
Telix Pharmaceuticals announced that the IPAX-2 study of TLX101-Tx has completed patient enrolment and confirmed dosing for newly diagnosed glioblastoma patients.
Educational webinar examines PSMA therapy portfolio approaches
April 28, 2026 | 10:47
The online seminar explored clinical strategies for prostate-specific membrane antigen targeting treatments in oncology practice.
BiPASS Prostate Cancer Study Begins Patient Dosing
January 19, 2026 | 15:27
The phase three clinical trial reached a milestone with its first American participant receiving treatment, advancing research into improved diagnostic approaches for prostate cancer detection.
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
March 21, 2025 | 07:38
Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has approved its New Drug Application for Gozellix® gozetotide injection), Telix's next-generation PSMA-PET imaging agent for prostate cancer.
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
March 18, 2025 | 05:52
Telix Pharmaceuticals Limited today announces that the Brazilian Health Regulatory Agency has approved Illuccix® the Company's lead prostate cancer imaging agent.
Latest News
Mobile Version